SSY GROUP - VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE - LETTER OF INTENT IN RELATION TO THE LICENSE OF CLASS 1 INNOVATIVE DRUG OPT101

1ST PROOF │ SSY │ 2602070 Ann E │ 2026/06/11/17:32 │ P02 │ 210mm X297mm

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE

LETTER OF INTENT IN RELATION TO

THE LICENSE OF CLASS 1 INNOVATIVE DRUG OPT101

This announcement is made by SSY Group Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

LETTER OF INTENT

The board of directors of the Company (the "Board") is pleased to announce that, on 12 June 2026 (after trading hours), Shijiazhuang No. 4 Pharmaceutical Co., Ltd. ("Shijiazhuang No. 4", a wholly-owned subsidiary of the Company) has entered into a letter of intent (the "LOI") with Opterion Health AG ("Opterion") in relation to the research, development, manufacturing and commercialization collaboration in respect of OPT101 ("OPT101") (under class 1 innovative drug), a novel non-glucose-based osmotic driver as an innovative treatment for patients on peritoneal dialysis (the "Possible Collaboration").

The principal terms of the LOI are set out as follows:

Exclusive license

Opterion shall grant to Shijiazhuang No. 4 an exclusive license in respect of the patents, technical knowhow and platform technologies pertaining to OPT101 for the research, development, manufacturing and sales of licensed products in the People's Republic of China (excluding Hong Kong, Macao and Taiwan Region) for a period ending in 2038. Shijiazhuang No. 4 shall also be entitled to priority rights in obtaining license for the research, development, manufacturing and distribution of OPT101 in Hong Kong, Taiwan Region and Russia in the future on the same terms and conditions.

1ST PROOF │ SSY │ 2602070 Ann E │ 2026/06/11/17:32 │ P02 │ 210mm X297mm

Formal agreement

It is expected that the results of the Phase I clinical trial data in the European Medicines Agency (the "EMA") would be available in the third quarter of 2026. Therefore, Opterion and Shijiazhuang No. 4 are committed to enter into a formal collaboration and licensing agreement (the "Formal Agreement") in the third quarter of 2026.

Priority Cooperation Right

Under the same conditions, Shijiazhuang No. 4 has the priority right to cooperate with Opterion in relation to OPT101 (the "Priority Cooperation Right"). If Opterion intends to choose a third party to participate in the project in relation to OPT101, Opterion shall give notice to Shijiazhuang No. 4 containing the cooperation conditions with the third party. Shijiazhuang No. 4 shall, within a prescribed time, elect whether to exercise the Priority Cooperation Right. The Priority Cooperation Right shall expire on 30 September 2026, subject to extension if the results of Phase I EMA clinical trials cannot be obtained by the third quarter of 2026.

Binding effect

The Possible Collaboration is subject to the Formal Agreement to be negotiated and entered into between Opterion and Shijiazhuang No. 4. The LOI shall be effective for a period of three (3) months commencing from the signing of the LOI (or, if earlier, until the entering into of a term sheet). Except for the clauses relating to confidentiality, non-compete and other general provisions, the LOI does not create binding obligations on the parties thereto.

INFORMATION ON OPTERION

Opterion Health AG is a Swiss-based biopharmaceutical company focused on transforming renal care through the development of novel therapies for peritoneal dialysis patients.

To the best of the knowledge, information and belief of the Board having made all reasonable enquiries, Opterion and its ultimate beneficial owner(s) are third parties independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")).

1ST PROOF │ SSY │ 2602070 Ann E │ 2026/06/11/17:32 │ P02 │ 210mm X297mm

REASONS FOR AND BENEFITS OF THE POSSIBLE COLLABORATION

The Group is principally engaged in the research, development, manufacturing and selling of pharmaceutical products, which includes finished medicines, bulk pharmaceuticals and medical materials.

The research and development of OPT101 represents an attempt to bring much-needed new therapy options to patients with renal failure. The development of OPT101 represents the first innovation of its kind in over 30 years in the field of peritoneal dialysis. OPT101 has the potential to address long- standing limitations in peritoneal dialysis by eliminating glucose-based osmotic agents, which are associated with metabolic distress and peritoneal dialysis complications. Should the clinical trial of OPT101 be successful, it could improve the quality of life of patients undergoing peritoneal dialysis and the outcome for those who rely on life-saving treatments. Renal diseases represent a major impact in the world with a fast-growing population of patients requiring peritoneal dialysis. The Company sees a substantial unmet demand in the peritoneal dialysis market. If the Possible Collaboration materialises, the Group would be able to benefit from the exclusive license of the patents and know-how pertaining to OPT101 to be granted to Shijiazhuang No. 4, which is expected to have a positive impact on the Group's growth and business development.

Having considered the above, the directors of the Company consider that the LOI and the Possible Collaboration contemplated thereunder are fair and reasonable and in the interests of the Company and its shareholders as a whole.

Further announcement(s) will be made by the Company in relation to the Possible Collaboration in accordance with the Listing Rules as and when appropriate.

As at the date of this announcement, no definitive agreement has been entered into between the parties in respect of the Possible Collaboration, and hence the Possible Collaboration may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 15 June 2026